BMS 986012

Drug Profile

BMS 986012

Alternative Names: Anti-fucosyl-GM1 - Bristol-Myers Squibb; BMS986012

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fucosyl GM1 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer

Most Recent Events

  • 08 Sep 2017 Initial efficacy and adverse events data from a phase I/II trial in Small cell lung cancer (Combination therapy, Second line therapy) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 29 Aug 2017 Bristol-Myers Squibb completes a phase I trial in Small cell lung cancer (Monotherapy) in Japan (IV) (NCT02949895)
  • 31 Oct 2016 Bristol-Myers Squibb plans a phase I trial for Small cell lung cancer in Japan (IV) (NCT02949895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top